Spero Therapeutics, Inc. (SPRO)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 50M 100M 150M Q4 '17: 2M Q1 '18: 3M Q2 '18: 3.2M Q3 '18: 3.3M Q4 '18: 4M Q1 '19: 10.5M Q2 '19: 12.2M Q3 '19: 16.2M Q4 '19: 18.1M Q1 '20: 12.1M Q2 '20: 11.7M Q3 '20: 11.1M Q4 '20: 9.3M Q1 '21: 14.9M Q2 '21: 18.4M Q3 '21: 17.4M Q4 '21: 18.3M Q1 '22: 13M Q2 '22: 9.9M Q3 '22: 8.8M Q4 '22: 53.5M Q1 '23: 53.5M Q2 '23: 54.2M Q3 '23: 77.7M Q4 '23: 103.8M Q1 '24: 111M Q2 '24: 118.5M Q3 '24: 106.5M Q4 '24: 48M Q1 '25: 44.6M Q2 '25: 48.6M Q3 '25: 40.5M Q4 '25: 66.8M Q1 '26: 61.2M Q2 '26: 47M Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-120M -80M -40M 0 40M 80M 120M Q2 '17: -34.5M Q3 '17: -36.5M Q4 '17: -41.7M Q1 '18: -44.9M Q2 '18: -44.8M Q3 '18: -45.7M Q4 '18: -42.8M Q1 '19: -37.7M Q2 '19: -41.4M Q3 '19: -48.4M Q4 '19: -63.2M Q1 '20: -80.3M Q2 '20: -85.2M Q3 '20: -86.2M Q4 '20: -79.1M Q1 '21: -75.7M Q2 '21: -75.8M Q3 '21: -79.3M Q4 '21: -88M Q1 '22: -98.8M Q2 '22: -106.3M Q3 '22: -95.6M Q4 '22: -42.2M Q1 '23: -26.2M Q2 '23: -13M Q3 '23: -3.1M Q4 '23: 21.5M Q1 '24: 21.7M Q2 '24: 15.6M Q3 '24: -1.1M Q4 '24: -73.4M Q1 '25: -74.1M Q2 '25: -57.5M Q3 '25: -46.8M Q4 '25: 6.3M Q1 '26: 13.5M Q2 '26: 6M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Net Income TTM

-120M -80M -40M 0 40M 80M 120M Q4 '16: -25.5M Q1 '17: -25.5M Q2 '17: -28.6M Q3 '17: -32.1M Q4 '17: -38.7M Q1 '18: -43.5M Q2 '18: -44.3M Q3 '18: -44.9M Q4 '18: -41.7M Q1 '19: -36.2M Q2 '19: -39.4M Q3 '19: -46.6M Q4 '19: -61M Q1 '20: -79.2M Q2 '20: -83.5M Q3 '20: -84.7M Q4 '20: -78.3M Q1 '21: -74.4M Q2 '21: -75.5M Q3 '21: -79.1M Q4 '21: -89.8M Q1 '22: -103.2M Q2 '22: -113.3M Q3 '22: -102.5M Q4 '22: -46.4M Q1 '23: -26.9M Q2 '23: -10.1M Q3 '23: -1.6M Q4 '24: -68.6M Q1 '25: -69.8M Q2 '25: -53.6M Q3 '25: -43.8M Q3 '17 Q3 '18 Q3 '19 Q3 '20 Q3 '21 Q3 '22 Q3 '23 Q3 '25

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-90M -60M -30M 0 30M 60M 90M Q3 '17: -35.6M Q4 '17: -39.1M Q1 '18: -44.1M Q2 '18: -43.9M Q3 '18: -38.9M Q4 '18: -39.6M Q1 '19: -38.6M Q2 '19: -42M Q3 '19: -46.2M Q4 '19: -50M Q1 '20: -62.4M Q2 '20: -75.3M Q3 '20: -86.9M Q4 '20: -85.9M Q1 '21: -78M Q2 '21: -69.7M Q3 '21: -53.4M Q4 '21: -64.3M Q1 '22: -77.1M Q2 '22: -83.6M Q3 '22: -79.6M Q4 '22: -7.7M Q1 '23: 7.6M Q2 '23: 12.1M Q3 '23: 29M Q4 '23: -33M Q1 '24: -14.2M Q2 '24: -14.4M Q3 '24: -17.5M Q4 '24: -23.4M Q1 '25: -33.4M Q2 '25: -32.3M Q3 '25: -27.7M Q4 '25: -12.6M Q1 '26: 7.2M Q2 '26: 19.6M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Free Cash Flow TTM

-90M -60M -30M 0 30M 60M 90M Q3 '19: -48.8M Q4 '19: -50.3M Q1 '20: -62.7M Q2 '20: -75.5M Q3 '20: -87.1M Q4 '20: -86M Q3 '19 Q4 '19 Q1 '20 Q2 '20 Q3 '20 Q4 '20

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 20M 40M 60M Q2 '21: 29.7M Q3 '21: 32.1M Q1 '22: 32.6M Q2 '22: 33M Q3 '22: 35.9M Q1 '23: 52.5M Q2 '23: 52.6M Q3 '23: 52.7M Q1 '24: 53.5M Q2 '24: 54M Q3 '24: 54.1M Q1 '25: 55.4M Q2 '25: 56M Q3 '25: 56.3M Q1 '26: 57.3M Q2 '26: 58M Q3 '21 Q2 '22 Q1 '23 Q3 '23 Q2 '24 Q1 '25 Q3 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-150.00 -100.00 -50.00 0.00 50.00 100.00 150.00 Q4 '16: -95.72 Q1 '17: -95.81 Q2 '17: -106.72 Q3 '17: -119.51 Q4 '17: -95.42 Q1 '18: -74.56 Q2 '18: -39.04 Q3 '18: -3.62 Q4 '18: -2.63 Q1 '19: -2.18 Q2 '19: -2.23 Q3 '19: -2.58 Q4 '19: -3.29 Q1 '20: -4.22 Q2 '20: -4.33 Q3 '20: -4.24 Q4 '20: -3.54 Q1 '21: -2.98 Q2 '21: -2.76 Q3 '21: -2.60 Q4 '21: -2.91 Q1 '22: -3.26 Q2 '22: -3.50 Q3 '22: -3.13 Q4 '22: -1.23 Q1 '23: -0.47 Q2 '23: 0.17 Q3 '23: 0.44 Q4 '24: -1.27 Q1 '25: -1.28 Q2 '25: -0.98 Q3 '25: -0.79 Q3 '17 Q3 '18 Q3 '19 Q3 '20 Q3 '21 Q3 '22 Q3 '23 Q3 '25

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.